Latest Health News

Charter Hall Long WALE REIT reports a $118.3 million statutory profit for FY25, reversing last year's heavy loss, while maintaining stable distributions and actively managing debt facilities.

REA Group has reported a robust FY25 with strong revenue and profit growth, underpinned by solid Australian market performance and strategic moves in India. The company also announced a leadership transition amid optimistic FY26 guidance.

Mayne Pharma has firmly rejected a fresh termination notice from Cosette Pharmaceuticals alleging breaches related to FDA disclosure, escalating an ongoing contractual dispute with significant legal implications.

Pinnacle Investment Management announces a fully franked dividend of AUD 0.27 per share for the half-year ending June 2025, offering shareholders a Dividend Reinvestment Plan with currency flexibility.

Nutritional Growth Solutions has completed a $760,000 share placement at a slight discount, aiming to boost inventory and support its retail growth strategy.

Nutritional Growth Solutions revises its Q2 FY25 financials, confirming stable revenue and detailing expanded distribution into CVS and Walmart. The company is actively raising capital to support growth and improve liquidity.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Trajan Group Holdings has reported record FY25 revenue of $166.5 million, exceeding guidance despite operational headwinds. However, EBITDA fell slightly short of forecasts, reflecting challenges in supply chains and market shifts.

HeraMED Limited has resumed trading on the ASX following the release of its quarterly reports and a significant capital raising announcement, marking a pivotal moment for the medical device company.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Telix Pharmaceuticals has recast its historical financials from AUD to USD to better reflect its US-centric revenue streams and reports increased operating expenditure tied to recent acquisitions and growth initiatives.